Influenza and Other Respiratory Viruses

Papers
(The H4-Index of Influenza and Other Respiratory Viruses is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
281
85
Infection‐induced seroconversion and seroprevalence of SARS‐CoV‐2 among a cohort of children and youth in Montreal, Canada81
Issue Information69
Issue Information66
Comparative complete scheme and booster effectiveness of COVID‐19 vaccines in preventing SARS‐CoV‐2 infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case–case study based on57
A novel household‐based patient outreach pilot program to boost late‐season influenza vaccination rates during the COVID‐19 pandemic53
Evaluating Bacillus Calmette–Guérin Polysaccharide Nucleic Acid as an Adjuvant for Influenza Vaccines in Mice49
SARS‐CoV‐2 infection rate in Antananarivo frontline health care workers, Madagascar45
Avian Influenza Virus (H5N1) Was Not Detected Among Dairy Cattle and Farm Workers in Pakistan43
Low prevalence of seasonal influenza viruses in Hong Kong, 202236
A comparative immune response to COVID‐19 vaccination between children and adults36
Antibiotic prescription for outpatients with influenza and subsequent hospitalisation: A cohort study using insurance data35
Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation35
Cost‐Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway33
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months32
EMARIS Conference 2023: Convergence of science, policy, and practice on acute respiratory infections in post COVID‐19 Eastern Mediterranean Region31
No evidence for HPAI H5N1 2.3.4.4b incursion into Australia in 202231
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial31
Cross‐Reactive Antibody Responses to Coronaviruses Elicited by SARS‐CoV‐2 Infection or Vaccination30
COVID‐19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024–May 202530
Antigenic Characterization of H1N1 Influenza Viruses That Circulated During the 2019–2020 Season in Philadelphia, Pennsylvania30
Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 t30
Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study29
Severe acute respiratory syndrome coronavirus 2 can be detected in exhaled aerosol sampled during a few minutes of breathing or coughing25
0.067208051681519